Posted by Michael Wonder on 16 Feb 2024
Japan first in the world to approve Dupixent for chronic spontaneous urticaria
16 February 2024 - Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo.
The Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorisation for Dupixent (dupilumab) for the treatment of chronic spontaneous urticaria in people aged 12 years and older whose disease is not adequately controlled with existing therapy.
